Gene product: plasminogen activator inhibitor, type II (arginine-serpin) [PAI2]
Alleles: A1, A2, A1, A2
Insert Size (kb)
1.870
Media
ATCC® Medium 1227: LB Medium (ATCC medium 1065) with 50 mcg/ml ampicillin
Biosafety Level
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Shipping Information
Distributed: freeze-dried
Comments
Restriction digests of the clone give the following sizes (kb): EcoRI--2.7, 1.88; PstI--4.27, 0.35; EcoRI/PstI--2.7, 1.52, 0.33; HindIII--4.54; XbaI--3.55, 0.99.
The insert contains the following restriction sites (in nucleotides from the 5' end): PstI--332; XbaI--785; DraI--1587.
The cell line was treated with phorbol myristae acetate (PMA) to induce differentiation.
The published sequence is 1881 nucleotides, including EcoRI linkers. The complete coding sequence extends from 32 through 1277.
Insert encodes the NNS variant of PAI-2.
The consensus sequence TTATTTAT, identified in cytokines that act as inflammatory mediators, occurs in the 3' untranslated region.
References
Schwartz C. The human gene for plasminogen activator inhibitor 2 (PAI2) exhibits an EcoRI RFLP. Nucleic Acids Res. 18: 2837, 1990. PubMed: 1971103
Schleuning WD, et al. Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells. Mol. Cell. Biol. 7: 4564-4567, 1987. PubMed: 3325828
Kruithof EK, et al. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 86: 4007-4024, 1995. PubMed: 7492756
